Pegs1
The supply agreement that CRTG entered into with Evonik is in the 10Q from Nov 12, 2020
"Supply Agreement
During June 2020, the Company entered into a supply agreement with Evonik Operations GmbH to purchase cyclohexasilane, Si6H12 (CHS) for $185,000 per 500 grams. The supply agreement is valid until March 31, 2021. The Company paid Evonik Operations GmbH $92,500 on July 20, 2020, to initiate production of CHS, in accordance with the agreement."
There is no mention of customers paying for the samples. However, the shareholder letter from July 22, 2020 on top of page 4 references Michael Kraft's statement on revenues in commercialization.
"And the last area in commercialization is revenues, which is important. This is going to depend on the sale of either products or selling a license, and we're discussing both with our customers. Given the timing of our customers getting CHS samples at the end of this year, and in Q1 of 2021, we see those negotiations taking place in the year of 2021. Now to give you a sense, licensing typically involves a general license fee upfront, and a royalty over years thereafter. Some licenses can be in the million-dollar range of a general license fee or more, and royalties have a wide range, really depending on the application.
Some companies that license try to get an exclusive license, and sometimes they try and get most of the cost of that overall license upfront in the general license fee. And if it's large enough of an application sometimes those customers would try and acquire the company, mostly for exclusivity. There is the possibility that Coretec could get acquired on that basis, but at this point it's just a matter of getting those initial applications, the traction with our customers, getting those volumes. And I think most of the applications we're looking at are some very large applications, so that's always a possibility"
News 
Market Data 
Discover 
